Literature DB >> 21142898

Which medication do I need to manage dizzy patients?

Doreen Huppert1, Michael Strupp, Harald Mückter, Thomas Brandt.   

Abstract

Vertigo and dizziness are not independent disease entities, but instead symptoms of various diseases. Accordingly, a variety of treatment approaches are required. Here we review the most relevant drugs for managing dizziness, vertigo, and nystagmus syndromes. It is important to differentiate symptomatic treatment of nausea and vomiting with, for example, dimenhydrinate and benzodiazepines, and prophylactic treatment of motion sickness with scopolamine from a causal therapy of the underlying disorders. Examples of such causal therapy include aminopyridines for downbeat nystagmus and episodic ataxia type 2; carbamazepine for vestibular paroxysmia, paroxsymal dysarthria and ataxia in multiple sclerosis, and superior oblique myokymia; betahistine, dexamethasone, and gentamicin for Menière's disease; gabapentin and memantine for different forms of acquired and congenital nystagmus; corticosteroids for acute vestibular neuritis and Cogan's syndrome; metoprolol and topiramate for vestibular migraine; and selective serotonin reuptake inhibitors such as paroxetine for phobic postural vertigo. The clinical entities are briefly described, the various medications are discussed in alphabetical order, and dosage, major side effects, contraindications, and alternative medications of each drug are displayed in boxes for easy reference.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21142898     DOI: 10.3109/00016489.2010.531052

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  8 in total

1.  Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.

Authors:  Jozef J P Nauta
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

2.  Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.

Authors:  G Desmadryl; S Gaboyard-Niay; A Brugeaud; C Travo; A Broussy; A Saleur; J Dyhrfjeld-Johnsen; E Wersinger; C Chabbert
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  Muscarinic Acetylcholine Receptors and M-Currents Underlie Efferent-Mediated Slow Excitation in Calyx-Bearing Vestibular Afferents.

Authors:  J Chris Holt; Paivi M Jordan; Anna Lysakowski; Amit Shah; Kathy Barsz; Donatella Contini
Journal:  J Neurosci       Date:  2017-01-16       Impact factor: 6.167

4.  A Pilot Study on the Efficacy of Continuous Positive Airway Pressure on the Manifestations of Ménière's Disease in Patients with Concomitant Obstructive Sleep Apnea Syndrome.

Authors:  Meiho Nakayama; Ayako Masuda; Kayoko Bhardwaj Ando; Sachie Arima; Kayoko Kabaya; Akira Inagaki; Yoshihisa Nakamura; Motohiko Suzuki; Hilary Brodie; Rodney C Diaz; Shingo Murakami
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

Review 5.  Management of peripheral vertigo with antihistamines: New options on the horizon.

Authors:  Jonas Dyhrfjeld-Johnsen; Pierre Attali
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

6.  A Perspective for Ménière's Disease: In Silico Investigations of Dexamethasone as a Direct Modulator of AQP2.

Authors:  Robin Mom; Julien Robert-Paganin; Thierry Mom; Christian Chabbert; Stéphane Réty; Daniel Auguin
Journal:  Biomolecules       Date:  2022-03-28

7.  Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.

Authors:  Fulvio Plescia; Pietro Salvago; Francesco Dispenza; Giuseppe Messina; Emanuele Cannizzaro; Francesco Martines
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

Review 8.  Meniere's Disease and Vestibular Migraine: Updates and Review of the Literature.

Authors:  Paul Tabet; Issam Saliba
Journal:  J Clin Med Res       Date:  2017-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.